Development and In-Vitro Drug Release Profile of Sustained release Floating Granules of Cinnarizine

  • Posted on: 31 July 2016
  • By: admin

 

Magazine Home


August 2016 ARTICLE LIST >>

PharmaTutor (August - 2016)

 

Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 8)

 

Received On: 01/03/2016; Accepted On: 03/04/2016; Published On: 01/08/2016

 

AUTHORS:
Aman Mittal
Smt. Tarawati Institute of Biomedical & Allied Science, Roorkee, HP, India
amanmittal_27@yahoo.com

 

ABSTRACT: Floating drug delivery systems (FDDS) are the drug delivery systems having a bulk density lower than the gastric content and they remain buoyant in the stomach for a prolonged period of time, with the potential for continuous release of drug. Cinnarizine, a H1-receptor antagonist, used for the treatment for vestibular vertigo disorders and motion sickness was selected as the drug aspirant and Gelucire 43/01 was selected as a lipid carrier in different ratio (1:0.5, 1:1, 1:1.5) along with drug to be formulated as gastro retentive multiparticulate system. The formulation F1 to F9 were prepared and formulation F4 to F9 were evaluated for in-vitro drug release and formulation F5 was selected as optimized formulation that exhibited good floating ability and zero order drug release (93.56 %) at the end of 8 hrs. The in-vitro drug release study of the aged sample show phase conversion of Gelucire. The phase conversion also caused increase in drug release. In conclusion, hydrophobic lipid, Gelucire 43/01 can be considered as an effective carrier for design of a multiple unit floating drug delivery system of cinnarizine.

 

How to cite this article: Mittal A; Development and In-Vitro Drug Release Profile of Sustained release Floating Granules of Cinnarizine; PharmaTutor; 2016; 4(8); 27-35

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML